Tuesday, Oct 27, 2020 2:00p -
Thursday, Oct 29, 2020 10:00p
Online, Online 00000
Lectures & Conferences
With the explosive excitement and clinical proof of concept utilizing CD47 approaches, 2020 is the year for macrophage development, as we witness greater interest and investment in new work on novel macrophage targets outside of CD47.
The Macrophage-directed Therapies Summit is focused on optimizing the potential of macrophage therapies, through direct utilization of cells or small molecule approaches to target and stimulate macrophage cells in vivo for oncological indications and beyond.
Join us virtually this October as the trailblazers of macrophage therapeutic development, from the likes of Carisma Therapeutics, Faron Pharmaceuticals, and Verseau Therapeutics come together to advance the fundamental understanding of macrophage biology, avoiding on-target toxicities and the emerging field of macrophage cellular immunotherapy.
Early booking and Academic discounts available - see website for more details.
+1 617 455 4188
Conference Only (Drug Developer Pricing) - DIGITAL : USD 2099.0,
Conference Only (Standard Pricing) - DIGITAL : USD 2449.0,
Conference Only (Academic Pricing) - DIGITAL : USD 1259.0
Speakers: Arun Kashyap, Vice President, Research, Arch Oncology, Sergio Trombetta, Senior Principal Scientist, Cancer Immunology and Immune Modulation, Boehringer Ingelheim, Michael Klichinsky, Co-Founder and VP, Discovery, Carisma Therapeutics, C. Wyatt Shields, IV Assistant Professor, Department of Chemical and Biological Engineering, University of Colorado Boulder, Juho Jalkanen, Chief Development Officer, Faron Pharmaceuticals, Dr. Nico Lachmann, Principle Investigator, Hannover Medical School, Jennifer Guerriero, Instructor in Medicine, Director, Harvard Medical School, Breast Tumor Immunology Laboratory, Dana- Farber Cancer Institute, Yaron Pereg, Chief Executive Officer, Kahr Medical, Mable Wing Yan Chan, PhD Candidate, Arthritis Program, Krembil Research Institute, University Health Network, Institute of Biomaterials and Biomedical Engineering, University of Toronto, Venkat Reddy, Chief Scientific Officer, Macrophage Pharma, Jeffrey Pollard, Director, Professor of Resilience Biology, Medical Research Council Centre for Reproductive Health, University of Edinburgh, Hung-Yen (Peter) Chou, Scientist, Oncoimmune, Yang Liu Founder, President and Chief Scientific Officer, Oncoimmune, Nicolas Poirier, Chief Scientific Officer, OSE Immunotherapeutics, Leonard Reyno, Chief Executive Officer, Pionyr Immunotherapeutics, Emmanuel Normant, VP Preclinical Sciences, TG Therapeutics, Gloria Lin, Associate Director of Translational Research, Trillium Therapeutics Inc., Bruce C. Trapnell, Professor of Medicine and Pediatrics, Director, University of Cincinnati College of Medicine, Translational Pulmonary Science Center, Cincinnati Children’s Hospital, Sowmya Viswanathan, Assistant Professor, Institute of Biomaterial and Biomedical Engineering, Scientist, University of Toronto, Krembil Research Institute, University Health Network, Dartha Puttta, Assistant Professor, University of Pittsburgh, Ashish Kulkarni, Assistant Professor of Chemical Engineering, University of Massachusetts Amherst, Igor Feldman, Vice President, Head of Computational Biology, Verseau Therapeutics, Tatiana Novobrantseva, Co-founder and Chief Scientific Officer, Verseau Therapeutics